



Pfizer Declares Third-Quarter 2020 Dividend

Thursday, June 25, 2020 - 12:14pm

.q4default .bwalignc { text-align: center; list-style-position: inside; }

Board of Directors approves quarterly cash dividend of \$0.38 per share

NEW YORK--(BUSINESS WIRE)-- The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company's common stock, payable September 1, 2020, to holders of the Common Stock of record at the close of business on July 31, 2020. The third-quarter 2020 cash dividend will be the 327th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.: Breakthroughs that change patients' lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

View source version on [businesswire.com](https://www.businesswire.com):

<https://www.businesswire.com/news/home/20200625005712/en/>

Pfizer Media: Amy Rose (212) 733-7410 Amy.Rose@pfizer.com

Pfizer Investor: Ryan Crowe (212) 733-8160 Ryan.Crowe@pfizer.com

Source: Pfizer Inc.